Startup Restores Sight to Stargardt Patient With Retinal Implant, Eyes Broader Brain-Computer Uses
Key takeaways
- PRIMA retinal implant successfully implanted in first Stargardt disease patient; patient recognized letters and read words during early rehab.
- Device uses 2mm chip with camera glasses; current limitations include narrow field of view and black-and-white vision.
- Science Corporation plans next-generation implant within one year, targeting near-native vision acuity within five years.
Science Corporation has completed its first implantation of PRIMA, a retinal prosthetic chip, in a patient with Stargardt disease—an inherited condition that gradually destroys central vision affecting roughly 150,000 people worldwide. The May procedure at Sydney Eye Hospital marked the company's expansion beyond geographic atrophy, the age-related condition for which PRIMA already has European approval. During rehabilitation, the patient recognized letters in the first session and read a word in the second.
The device works by replacing degenerated photoreceptors with a 2mm implant paired to camera-equipped glasses that stream visual data to the chip. Current limitations include a narrow field of view and black-and-white output, though the image quality is sharp and high-contrast. CEO Max Hodak, formerly Neuralink's president, framed the technology as a brain-computer interface rather than a standalone medical device, emphasizing that vision is fundamentally electrical signaling along the optic nerve.
The bigger picture
Hodak's reframing of retinal implants as BCIs positions Science Corporation distinctly from competitors like Second Sight and Bionic Sight, which market vision restoration more narrowly. The timeline he sketched—next-generation implants within a year and near-native acuity within five years—sets an aggressive benchmark. Key technical hurdles remain: expanding the implant's footprint while managing eye curvature and shrinking electrodes. Success here validates the broader BCI approach and could accelerate funding for Science Corporation's skull-mounted brain sensors currently in development.
We're tracking this because it sits at the intersection of neurotechnology and medical device breakthroughs. Hodak's journey from Neuralink to Science Corporation is worth following—his framing of vision restoration as infrastructure for wider brain-computer applications reflects how the field is maturing. Early patient outcomes matter enormously here; regulatory pathways and real-world usability will shape what comes next.
As an Amazon Associate, LagPing earns from qualifying purchases. Product links are affiliate links.
You might also like
When AI ambitions collapse: inside the startup graveyard and big tech's failed experiments
Oct 25
Startup Pitches AI-Powered Chip Design to Break the Computing Bottleneck
Oct 15
AI-Powered Hardware Design Startup Flow Lands $50M in Series B, Hits $750M Valuation
Oct 1
Peak XV doubles down on seed bets with $5M per startup, backs 18 new ventures
Sep 29